Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
Wedbush Reiterates Neutral on Logitech International, Maintains $80 Price Target
Wedbush analyst Alicia Reese reiterates Logitech International (NASDAQ:LOGI) with a Neutral and maintains $80 price target.
Should you buy Microsoft before today’s earnings announcement?
As Microsoft gears up to reveal its quarterly earnings after the market closes, all eyes are on the tech giant,…